Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Efficacy of Cladribine (2-CdA) in Advanced Systemic Mastocytosis.
Helbig G, Koclęga A, Gaweł WB, Włodarczyk M, Rodzaj M, Łabędź A, Hus I, Raźny M. Helbig G, et al. Among authors: rodzaj m. Indian J Hematol Blood Transfus. 2020 Oct;36(4):661-666. doi: 10.1007/s12288-020-01279-8. Epub 2020 Apr 15. Indian J Hematol Blood Transfus. 2020. PMID: 33093752 Free PMC article.
High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group.
Hus I, Mańko J, Jawniak D, Jurczyszyn A, Charliński G, Poniewierska-Jasak K, Usnarska-Zubkiewicz L, Sawicki M, Druzd-Sitek A, Świderska A, Kopińska A, Grząśko N, Raźny M, Wędłowska A, Perzyński A, Gałązka A, Dytfeld D, Kubicki T, Rodzaj M, Waszczuk-Gajda A, Drozd-Sokołowska J, Pogłódek B, Pasternak A, Długosz-Danecka M, Szymczyk A, Dmoszyńska A. Hus I, et al. Among authors: rodzaj m. Oncol Lett. 2019 Dec;18(6):5811-5820. doi: 10.3892/ol.2019.10929. Epub 2019 Sep 27. Oncol Lett. 2019. PMID: 31788054 Free PMC article.
Exquisite response to imatinib mesylate in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome: a 12-year experience of the Polish Hypereosinophilic Syndrome Study Group.
Helbig G, Lewandowski K, Świderska A, Rodzaj M, Seferyńska I, Gajkowska-Kulik J. Helbig G, et al. Among authors: rodzaj m. Pol Arch Intern Med. 2020 Mar 27;130(3):255-257. doi: 10.20452/pamw.15224. Epub 2020 Mar 3. Pol Arch Intern Med. 2020. PMID: 32125294 Free article. No abstract available.
Primary refractory multiple myeloma: a real-world experience with 85 cases.
Jurczyszyn A, Waszczuk-Gajda A, Castillo JJ, Krawczyk K, Stork M, Pour L, Usnarska-Zubkiewicz L, Potoczek S, Hus I, Davila Valls J, Hari P, Chhabra S, Gentile M, Mikala G, Varga G, Chim CS, Fiala M, Vij R, Schutz N, Rodzaj M, Porowska A, Vesole DH, Druzd-Sitek A, Walewski J, Nooka AK. Jurczyszyn A, et al. Among authors: rodzaj m. Leuk Lymphoma. 2020 Dec;61(12):2868-2875. doi: 10.1080/10428194.2020.1788014. Epub 2020 Jul 5. Leuk Lymphoma. 2020. PMID: 32623944
Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.
Jurczyszyn A, Radocha J, Davila J, Fiala MA, Gozzetti A, Grząśko N, Robak P, Hus I, Waszczuk-Gajda A, Guzicka-Kazimierczak R, Atilla E, Mele G, Sawicki W, Jayabalan DS, Charliński G, Szabo AG, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Avivi I, Rodzaj M, Leleu X, Richez V, Knopińska-Posłuszny W, Masternak A, Yee AJ, Barchnicka A, Druzd-Sitek A, Guerrero-Garcia T, Liu J, Vesole DH, Castillo JJ. Jurczyszyn A, et al. Among authors: rodzaj m. Br J Haematol. 2018 Mar;180(6):831-839. doi: 10.1111/bjh.15092. Epub 2018 Jan 7. Br J Haematol. 2018. PMID: 29315478 Free article. Clinical Trial.
Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia.
Helbig G, Moskwa A, Hus M, Piszcz J, Swiderska A, Urbanowicz A, Całbecka M, Seferyńska I, Raźny M, Rodzaj M, Żuk E, Kyrcz-Krzemień S. Helbig G, et al. Among authors: rodzaj m. Cancer Chemother Pharmacol. 2011 Apr;67(4):967-9. doi: 10.1007/s00280-011-1582-3. Epub 2011 Feb 17. Cancer Chemother Pharmacol. 2011. PMID: 21327932 Free PMC article. No abstract available.
Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study.
Mądry K, Lis K, Biecek P, Młynarczyk M, Rytel J, Górka M, Kacprzyk P, Dutka M, Rodzaj M, Bołkun Ł, Krochmalczyk D, Łątka E, Drozd-Sokołowska J, Waszczuk-Gajda A, Knopińska-Posłuszny W, Kopińska A, Subocz E, Masternak A, Guzicka-Kazimierczak R, Gil L, Machowicz R, Biliński J, Giebel S, Czerw T, Dwilewicz-Trojaczek J. Mądry K, et al. Among authors: rodzaj m. Clin Lymphoma Myeloma Leuk. 2019 May;19(5):264-274.e4. doi: 10.1016/j.clml.2019.01.002. Epub 2019 Jan 23. Clin Lymphoma Myeloma Leuk. 2019. PMID: 30898482